• Sankalp P Patel, Brian J Solomon, Robert D Pascotto, Stephen E D'Orazio, Elsy V Navas, Robert J Cubeddu, and Gaston A Cudemus.
• Department of Internal Medicine, Graduate Medical Education, NCH Healthcare System, Naples, FL. Electronic address: Sankalp.Patel@nchmd.org.
• J. Cardiothorac. Vasc. Anesth. 2022 Aug 1; 36 (8 Pt B): 319732013197-3201.

AbstractOften labeled the forgotten ventricle, the right ventricle's (RV) importance has been magnified over the last 2 years as providers witnessed how severe acute respiratory syndrome coronavirus 2 infection has a predilection for exacerbating RV failure. Venovenous extracorporeal membranous oxygenation (VV-ECMO) has become a mainstay treatment modality for a select patient population suffering from severe COVID-19 acute respiratory distress syndrome. Concomitant early implementation of a right ventricular assist device with ECMO (RVAD-ECMO) may confer benefit in patient outcomes. The underlying mechanism of RV failure in COVID-19 has a multifactorial etiopathogenesis; nonetheless, clinical evaluation of a patient necessitating RV support remains unchanged. Herein, the authors report the case of a critically ill patient who was transitioned from a conventional VV-ECMO Medtronic Crescent cannula to RVAD-ECMO, with the insertion of the LivaNova ProtekDuo dual-lumen RVAD cannula.Published by Elsevier Inc.

22 keywords...

hide…